US Pharma MarketingNew heights for NewLimit as anti-aging biotech nabs $435M to rejuvenate old cells
Anti-aging startup NewLimit is back with a fresh fundraise of $435 million after landing on its first clinic-ready can Anti-aging startup NewLimit is back with a fresh fundraise of $435 million after landing on its first clinic-ready candidate years earlier than expected.
Anti-aging startup NewLimit is back with a fresh fundraise of $435 million after landing on its first clinic-ready candidate years earlier than expected.
Source: FierceBiotech